Global DNA Damage Response Drugs Market

Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Published Year: 2020
SKU: BHP0942SA

3500

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Product Definition

1.1    Inclusion and Exclusion

2 Research Scope

2.1    Scope of the Study
2.2    Key Questions Answered in the Report

3 Research Methodology

3.1    DNA Damage Response Drugs in Oncology: Research Methodology
3.2    Data Sources
         3.2.1    Primary Data Sources
         3.2.2    Secondary Data Sources
3.3    Market Estimation Model

4 Market Overview

4.1    Introduction
4.2    Importance of DDR Pathways in Oncology
4.3    Key Strategies for Targeting DDR Pathways
4.4    DDR Drugs Commercialization Landscape
4.5    COVID-19 Impact on Oncology Clinical Research
4.6    Market Size and Growth Potential, $Million, 2019-2030
         4.6.1    North America
         4.6.2    Europe
         4.6.3    Asia-Pacific (APAC)
         4.6.4    Latin America (LATAM)
         4.6.5    Rest-of-the-World (RoW)

5 Industry Insights

5.1    Overview
5.2    Legal Requirements and Frameworks in the U.S.
         5.2.1    Clinical Trial Authorization
         5.2.2    Marketing Authorization
         5.2.3    Post-Authorization Regulations
5.3    Legal Requirements and Frameworks in Europe
         5.3.1    Centralized Procedure
         5.3.2    Decentralized Procedure
         5.3.3    Mutual-Recognition Procedure
         5.3.4    National Procedure
5.4    Legal Requirements and Frameworks in Asia-Pacific
         5.4.1    China
         5.4.2    Japan
5.5    Patent Analysis

6 Market Dynamics

6.1    Overview
6.2    Impact Analysis
6.3    Market Drivers
         6.3.1    Rising Global Prevalence of Cancer
         6.3.2    Favorable Regulatory Environment
         6.3.3    Increasing Oncology R&D Expenditure
         6.3.4    Increase in Adoption of Precision Medicine in Cancer Treatment
6.4    Market Restraints
         6.4.1    High Cost Hindering the Adoption Rate
         6.4.2    Unfavorable Reimbursement Scenario
         6.4.3    Safety Concerns Pertaining to Severe Adverse Effects
6.5    Market Opportunity
         6.5.1    Massive scope in Emerging Regions

7 Competitive Landscape

7.1    Key Strategies and Developments
         7.1.1    Product Approvals and Other Activities
         7.1.2    Synergistic Activities
         7.1.3    Product Launch and Updradations
         7.1.4    Business Expansion and Funding
         7.1.5    Mergers and Acquisitions
7.2    Market Share Analysis, 2018-2019
7.3    Growth Share Analysis (by Commercialized Drugs)

8 Epidemiology Analysis for DNA Damage Response Drugs

Epidemiology Analysis for DNA Damage Response Drugs

9 Clinical Landscape

9.1    By Phase of Development
9.2    By DDR Pathway Target
9.3    By Oncology Specialty

10 Global DNA Damage Response Drugs Market, by Commercialized Drugs ($Million), 2019-2030

10.1    Overview
10.2    Lynparza
10.3    Talzenna
10.4    Zejula
10.5    Rubraca

11 DNA Damage Response Drugs, by Potential Pipeline Drugs

11.1    Overview
11.2    PARP Inhibitor
           11.2.1    Phase III
                         11.2.1.1    Pamiparib
                         11.2.1.2    Veliparib
                         11.2.1.3    Fluzoparib
           11.2.2    Phase II
           11.2.3    Phase I
11.3    WEE1 Kinase Inhibitor
           11.3.1    Phase I
11.4    ATR Kinase Inhibitor
           11.4.1    Phase II
           11.4.2    Phase I
11.5    Aurora B Kinase Inhibitor
           11.5.1    Phase II
11.6    DNA-PK Inhibitors
           11.6.1    Phase II
           11.6.2    Phase I
11.7    Others
           11.7.1    Phase II
           11.7.2    Phase I

12 Global DNA Damage Response Drugs Market, by Application, ($Million), 2019-2030

12.1    Overview
12.2    Ovarian Cancer
12.3    Breast Cancer
12.4    Pancreatic Cancer
12.5    Prostate Cancer

13 Global DNA Damage Response Drugs Market, by Region ($Million), 2019-2030

13.1    Overview
13.2    North America
           13.2.1    U.S.
           13.2.2    Canada
13.3    Europe
           13.3.1    Germany
           13.3.2    France
           13.3.3    U.K.
           13.3.4    Italy
           13.3.5    Spain
           13.3.6    Switzerland
           13.3.7    Rest-of-Europe
13.4    Asia-Pacific
           13.4.1    China
           13.4.2    Japan
           13.4.3    India
           13.4.4    Australia
           13.4.5    Rest-of-APAC
13.5    Latin America
           13.5.1    Brazil
           13.5.2    Rest-of-Latin America
13.6    Rest-of-the-World

14 Company Profiles

14.1    Overview
14.2    AbbVie Inc.
           14.2.1    Company Overview
           14.2.2    Role of AbbVie Inc. in Global DNA Damage Response Drugs Market
           14.2.3    Financials
           14.2.4    Key Insights about Financial Health of the Company
           14.2.5    SWOT Analysis
14.3    AstraZeneca plc
           14.3.1    Company Overview
           14.3.2    Role of AstraZeneca plc in Global DNA Damage Response Drugs Market
           14.3.3    Financials
           14.3.4    Key Insights about Financial Health of the Company
           14.3.5    SWOT Analysis
14.4    Bayer AG
           14.4.1    Company Overview
           14.4.2    Role of Bayer AG in Global DNA Damage Response Drugs Market
           14.4.3    Financials
           14.4.4    Key Insight about Financial Health of the Company
           14.4.5    SWOT Analysis
14.5    BeiGene, Ltd.
           14.5.1    Company Overview
           14.5.2    Role of BeiGene, Ltd. in Global DNA Damage Response Drugs Market
           14.5.3    Financials
           14.5.4    Key Insights about Financial Health of the Company
           14.5.5    SWOT Analysis
14.6    Clovis Oncology
           14.6.1    Company Overview
           14.6.2    Role of Clovis Oncology in Global DNA Damage Response Drugs Market
           14.6.3    Financials
           14.6.4    Key Insights about Financial Health of the Company
           14.6.5    SWOT Analysis
14.7    Debiopharm International SA
           14.7.1    Company Overview
           14.7.2    Role of Debiopharm International SA in Global DNA Damage Response Drugs Market
           14.7.3    SWOT Analysis
14.8    Eli Lilly & Company
           14.8.1    Company Overview
           14.8.2    Role of Eli Lilly & Company in Global DNA Damage Response Drugs Market
           14.8.3    Financials
           14.8.4    Key Insights about Financial Health of the Company
           14.8.5    SWOT Analysis
14.9    GlaxoSmithKline plc
           14.9.1    Company Overview
           14.9.2    Role of GlaxoSmithKline plc in Global DNA Damage Response Drugs Market
           14.9.3    Financials
           14.9.4    Key Insights about Financial Health of the Company
           14.9.5    SWOT Analysis
14.10    Merck KGaA
             14.10.1    Company Overview
             14.10.2    Role of Merck KGaA in Global DNA Damage Response Drugs Market
             14.10.3    Financials
             14.10.4    Key Insights about Financial Health of the Company
             14.10.5    SWOT Analysis
14.11    NMS Group S.p.A
             14.11.1    Company Overview
             14.11.2    Role of NMS Group S.p.A in Global DNA Damage Response Drugs Market
             14.11.3    SWOT Analysis
14.12    Onxeo SA
             14.12.1    Company Overview
             14.12.2    Role of Onxeo SA in Global DNA Damage Response Drugs Market
             14.12.3    Financials
             14.12.4    Key Insights about Financial Health of the Company
             14.12.5    SWOT Analysis
14.13    Pfizer Inc.
             14.13.1    Company Overview
             14.13.2    Role of Pfizer Inc. in Global DNA Damage Response Drugs Market
             14.13.3    Financials
             14.13.4    Key Insights about Financial Health of the Company
             14.13.5    SWOT Analysis
14.14    Repare Therapeutics
             14.14.1    Company Overview
             14.14.2    Role of Repare Therapeutics in Global DNA Damage Response Drugs Market
             14.14.3    SWOT Analysis
14.15    Sierra Oncology, Inc.
             14.15.1    Company Overview
             14.15.2    Role of Sierra Oncology, Inc. in Global DNA Damage Response Drugs Market
             14.15.3    Financials
             14.15.4    Key Insights about Financial Health of the Company
             14.15.5    SWOT Analysis
14.16    Zentalis Pharmaceuticals, LLC
             14.16.1    Company Overview
             14.16.2    Role of Zentalis Pharmaceuticals, LLC in Global DNA Damage Response Drugs Market
             14.16.3    SWOT Analysis

List of Tables

Table 4.1:    Approved DNA Damage Response Drugs, May 2020
Table 6.1:    Impact Analysis of Market Drivers
Table 6.2:    Impact Analysis of Market Restraints
Table 6.3:    Comparison of R&D Expenditure of Major Companies in Global DNA Damage Response Drugs Market, $Million, 2019 and 2018
Table 8.1:    Cancer Types Treated with DNA Damage Response Drugs
Table 11.1:    Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.2:    Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.3:    Pipeline of WEE1 Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.4:    Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.5:    Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.6:    Pipeline of Aurora B Kinase Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.7:    Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.8:    Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
Table 11.9:    Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
Table 11.10:    Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
Table 12.1:    Marketed DNA Damage Response (DDR) Drugs for Ovarian Cancer
Table 12.2:    DNA Damage Response (DDR) Drugs for Ovarian Cancer: Pipeline Products
Table 12.3:    Marketed DNA Damage Response (DDR) Drugs for Breast Cancer
Table 12.4:    DNA Damage Response (DDR) Drugs for Breast Cancer: Pipeline Products
Table 12.5:    Marketed DNA Damage Response (DDR) Drugs for Pancreatic Cancer
Table 12.6:    DNA Damage Response (DDR) Drugs for Pancreatic Cancer: Pipeline Products
Table 12.7:    Marketed DNA Damage Response (DDR) Drugs for Prostate Cancer
Table 12.8:    DNA Damage Response (DDR) Drugs for Prostate Cancer: Pipeline Products

List of Figures

Figure 1:    Global Prevalence of Prostate and Breast Cancer, 2012-2017
Figure 2:    Steps for Obtaining Marketing Authorization in the U.S.
Figure 3:    Clinical Landscape of DNA Damage Response Drugs, by Phase of Development
Figure 4:    Clinical Landscape of DNA Damage Response Drugs, by Pathway Target
Figure 5:    Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
Figure 6:    Global Target Population of DNA Damage Response Drugs, 2020-2030
Figure 7:    Impact Analysis of Market Drivers and Market Challenges on the Global DNA Damage Response Drugs Market
Figure 8:    Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019 vs. 2030 ($Million)
Figure 9:    Expected Revenue of DNA Damage Response Drugs, by Potential Pipeline Drugs, 2025 vs. 2030
Figure 10:    Global DNA Damage Response Drugs Market, by Application, 2019 vs. 2030 ($Million)
Figure 11:    Global DNA Damage Response Drugs Market Snapshot
Figure 2.1:    Global DNA Damage Response Drugs Market Segmentation
Figure 3.1:    Global DNA Damage Response Drugs Market: Research Methodology
Figure 3.2:    Bottom-up Approach (Segment-Wise Analysis)
Figure 3.3:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Underlying Pathway of DNA Damage and Repair
Figure 4.2:    Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
Figure 4.3:    North America DNA Damage Response Drugs Market, 2019 and 2030
Figure 4.4:    Europe DNA Damage Response Drugs Market, 2019-2030
Figure 4.5:    Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
Figure 4.6:    Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 5.1:    Steps for Obtaining Marketing Authorization
Figure 5.2:    Share of Patents (by Ownership), 2016-2019
Figure 6.1:    Global Prevalence of Breast, Prostate, and Ovarian Cancer, 2013-2017
Figure 7.1:    Share of Key Developments and Strategies, January 2016 – May 2020
Figure 7.2:    Product Approvals and Other Activities Share (by Company), January 2016 –  May 2020
Figure 7.3:    Synergistic Activities Share (by Company), January 2016 – May 2020
Figure 7.4:    Product Launch and Upgradations Share (by Company), January 2016 –  May 2020
Figure 7.5:    Business Expansion and Funding Share (by Company), January 2016 –  May 2020
Figure 7.6:    Mergers and Acquisitions Share (by Company), January 2016 – May 2020
Figure 7.7:    Market Share Analysis for Global DNA Damage Response Drugs Market,  2018 and 2019
Figure 7.8:    Growth-Share Analysis for Global DNA Damage Response Drugs Market, (by Commercialized Drugs), 2019
Figure 8.1:    Global Prevalence of Ovarian Cancer (2012-2017)
Figure 8.2:    Global Prevalence of Breast Cancer (2012-2017)
Figure 8.3:    Global Prevalence of Prostate Cancer (2012-2017)
Figure 8.4:    Global Prevalence of Pancreatic Cancer (2012-2017)
Figure 8.5:    Global Target Population of Ovarian Cancer (2020-2030)
Figure 8.6:    Global Target Population of Breast Cancer (2020-2030)
Figure 8.7:    Global Target Population of Pancreatic Cancer (2020-2030)
Figure 8.8:    Global Target Population of Prostate Cancer (2020-2030)
Figure 9.1:    DNA Damage Response Drugs: Developmental Phases
Figure 9.2:    DNA Damage Response Drugs, by Pathway Target
Figure 9.3:    DNA Damage Response Drugs: by Oncology Specialty
Figure 10.1:    Global DNA Damage Response Drugs Market, by Commercialized Drugs,  2019-2030
Figure 10.2:    Global Revenue for Lynparza, 2019-2030
Figure 10.3:    Treatment Flow of Lynparza for Each Indication
Figure 10.4:    Global Revenue for Talzenna, 2019-2030
Figure 10.5:    Treatment Flow of Talzenna for Each Indication
Figure 10.6:    Global Revenue for Zejula, 2019-2030
Figure 10.7:    Treatment Plan of Zejula for Each Indication
Figure 10.8:    Global Revenue for Rubraca, 2019-2030
Figure 10.9:    Treatment Plan of Rubraca for Each Indication
Figure 11.1:    Expected Revenue for Pamiparib (by Late Phase), 2025-2030
Figure 11.2:    Expected Revenue for Veliparib (by Late Phase), 2025-2030
Figure 11.3:    Expected Revenue for Fluzoparib (by Late Phase), 2025-2030
Figure 12.1:    Global DNA Damage Response Drugs Market (by Application)
Figure 12.2:    Global DNA Damage Response Drugs Market (by Application), 2019-2030
Figure 12.3:    Global DNA Damage Response Drugs Market (by Ovarian Cancer), 2019-2030
Figure 12.4:    Global DNA Damage Response Drugs Market (by Breast Cancer), 2019-2030
Figure 12.5:    Global DNA Damage Response Drugs Market (by Pancreatic Cancer),  2019-2030
Figure 12.6:    Global DNA Damage Response Drugs Market (by Prostate Cancer), 2019-2030
Figure 13.1:    Global DNA Damage Response Drugs Market Snapshot (by Region)
Figure 13.2:    Global DNA Damage Response Drugs Market (by Region), 2019-2030
Figure 13.3:    Global DNA Damage Response Drugs Market Share (by Region),  2019 and 2030
Figure 13.4:    North America DNA Damage Response Drugs Market, 2019-2030
Figure 13.5:    North America: Market Dynamics
Figure 13.6:    North America DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.7:    U.S. DNA Damage Response Drugs Market, 2019-2030
Figure 13.8:    Canada DNA Damage Response Drugs Market, 2019-2030
Figure 13.9:    Europe DNA Damage Response Drugs Market, 2019-2030
Figure 13.10:    Europe Market Dynamics
Figure 13.11:    Europe DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.12:    Germany DNA Damage Response Drugs Market, 2019-2030
Figure 13.13:    France DNA Damage Response Drugs Market, 2019-2030
Figure 13.14:    U.K. DNA Damage Response Drugs Market, 2019-2030
Figure 13.15:    Italy DNA Damage Response Drugs Market, 2019-2030
Figure 13.16:    Spain DNA Damage Response Drugs Market, 2019-2030
Figure 13.17:    Switzerland DNA Damage Response Drugs Market, 2019-2030
Figure 13.18:    Rest-of-Europe DNA Damage Response Drugs Market, 2019-2030
Figure 13.19:    Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
Figure 13.20:    APAC: Market Dynamics
Figure 13.21:    APAC DNA Damage Response Drugs Market (by Country), 2019-2030
Figure 13.22:    China DNA Damage Response Drugs Market, 2019-2030
Figure 13.23:    Japan DNA Damage Response Drugs Market, 2019-2030
Figure 13.24:    India DNA Damage Response Drugs Market, 2019-2030
Figure 13.25:    Australia DNA Damage Response Drugs Market, 2019-2030
Figure 13.26:    RoAPAC DNA Damage Response Drugs Market, 2019-2030
Figure 13.27:    Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 13.28:    Latin America: Market Dynamics
Figure 13.29:    Latin America DNA Damage Response Drugs Market (by Country),  2019-2030
Figure 13.30:    Brazil DNA Damage Response Drugs Market, 2019-2030
Figure 13.31:    Rest-of-Latin America DNA Damage Response Drugs Market, 2019-2030
Figure 13.32:    RoW DNA Damage Response Drugs Market, 2019-2030
Figure 14.1:    Total Number of Companies Profiled
Figure 14.2:    AbbVie Inc.: Pipeline Product Portfolio
Figure 14.3:    AbbVie Inc.: Overall Financials, 2017-2019
Figure 14.4:    AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 14.5:    AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 14.6:    AbbVie Inc.: SWOT Analysis
Figure 14.7:    AstraZeneca plc: Overall Product Portfolio
Figure 14.8:    AstraZeneca plc: Pipeline Product Portfolio
Figure 14.9:    AstraZeneca plc: Overall Financials, 2017-2019
Figure 14.10:    AstraZeneca plc: Revenue (by Segment), 2017-2019
Figure 14.11:    AstraZeneca plc: Revenue (by Region), 2017-2019
Figure 14.12:    AstraZeneca plc: R&D Expenditure, 2017-2019
Figure 14.13:    AstraZeneca plc: SWOT Analysis
Figure 14.14:    Bayer AG: Pipeline Product Portfolio
Figure 14.15:    Bayer AG: Overall Financials, 2017-2019
Figure 14.16:    Bayer AG: Revenue (by Segment), 2018-2019
Figure 14.17:    Bayer AG: Revenue (by Region), 2017-2019
Figure 14.18:    Bayer AG: R&D Expenditure, 2017-2019
Figure 14.19:    Bayer AG: SWOT Analysis
Figure 14.20:    BeiGene, Ltd.: Pipeline Product Portfolio
Figure 14.21:    BeiGene, Ltd.: Overall Financials: 2017-2019
Figure 14.22:    BeiGene, Ltd.: Revenue (by Region), 2017-2019
Figure 14.23:    BeiGene, Ltd.: R&D Expenditure, 2017-2019
Figure 14.24:    BeiGene, Ltd.: SWOT Analysis
Figure 14.25:    Clovis Oncology: Overall Product Portfolio
Figure 14.26:    Clovis Oncology: Pipeline Product Portfolio
Figure 14.27:    Clovis Oncology: Overall Financials, 2017-2019
Figure 14.28:    Clovis Oncology: R&D Expenditure, 2017-2019
Figure 14.29:    Clovis Oncology: SWOT Analysis
Figure 14.30:    Debiopharm International SA: Pipeline Product Portfolio
Figure 14.31:    Debiopharm International SA: SWOT Analysis
Figure 14.32:    Eli Lilly & Company: Pipeline Product Portfolio
Figure 14.33:    Eli Lilly & Company: Overall Financials, 2017-2019
Figure 14.34:    Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 14.35:    Eli Lilly & Company: SWOT Analysis
Figure 14.36:    GlaxoSmithKline plc: Overall Product Portfolio
Figure 14.37:    GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 14.38:    GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 14.39:    GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 14.40:    GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 14.41:    GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 14.42:    GlaxoSmithKline plc: SWOT Analysis
Figure 14.43:    Merck KGaA: Pipeline Product Portfolio
Figure 14.44:    Merck KGaA: Overall Financials, 2017-2019
Figure 14.45:    Merck KGaA: Revenue (by Segment), 2017-2019
Figure 14.46:    Merck KGaA: Revenue (by Region), 2017-2019
Figure 14.47:    Merck KGaA: R&D Expenditure, 2017-2019
Figure 14.48:    Merck KGaA: SWOT Analysis
Figure 14.49:    NMS Group S.p.A: Pipeline Product Portfolio
Figure 14.50:    NMS Group S.p.A: SWOT Analysis
Figure 14.51:    Onxeo SA: Pipeline Product Portfolio
Figure 14.52:    Onxeo SA: Overall Financials, 2017-2019
Figure 14.53:    Onxeo SA: Revenue (by Segment), 2017-2019
Figure 14.54:    Onxeo SA: Revenue (by Region), 2017
Figure 14.55:    Onxeo SA: Revenue (by Region), 2018-2019
Figure 14.56:    Onxeo SA: R&D Expenditure (by Region), 2018-2019
Figure 14.57:    Onxeo SA: SWOT Analysis
Figure 14.58:    Pfizer Inc.: Overall Product Portfolio
Figure 14.59:    Pfizer Inc.: Pipeline Product Portfolio
Figure 14.60:    Pfizer Inc.: Overall Financials, 2017-2019
Figure 14.61:    Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 14.62:    Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 14.63:    Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 14.64:    Pfizer Inc.: R&D Expenditure, 2017-2019
Figure 14.65:    Pfizer Inc.: SWOT Analysis
Figure 14.66:    Repare Therapeutics: Pipeline Product Portfolio
Figure 14.67:    Repare Therapeutics: SWOT Analysis
Figure 14.68:    Sierra Oncology, Inc.: Pipeline Product Portfolio
Figure 14.69:    Sierra Oncology, Inc.: Overall Financials, 2017-2019
Figure 14.70:    Sierra Oncology, Inc.: R&D Expenditure, 2017-2019
Figure 14.71:    Sierra Oncology, Inc.: SWOT Analysis
Figure 14.72:    Zentalis Pharmaceuticals, LLC: Pipeline Product Portfolio
Figure 14.73:    Zentalis Pharmaceuticals, LLC: SWOT Analysis

You may also like

Published Year: 2019

Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Compet

The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated...

 
Published Year: 2018

Global Metastatic Cancer Treatment Market : Focus on Drugs, Competitive Landscape, and Country - Ana

The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is...

 

Global DNA Damage Response Drugs Market

Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030